H.C. Wainwright Maintains a Buy on Halozyme Therapeutics (HALO), Keeps the PT at $90

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90.

The analyst supported the optimistic rating with the company’s growth potential and the stability of its financial prospects, citing the recent success of the MajesTEC-3 trial that showed considerable improvements in progression-free survival (PFS) and overall survival (OS) compared to existing treatments.

The MajesTEC-3 trial pairs Johnson & Johnson’s DARZALEX Faspro with TECVAYLI. According to the analyst, the trial’s outcome boosts Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) royalty base and bolsters evidence for DARZALEX-based regimens, as DARZALEX Faspro is powered by the company’s ENHANZE technology.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

While we acknowledge the potential of HALO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.